

For Immediate Release
July 31, 2019

ISMP Canada supports Long-Term Care Public Inquiry Recommendations

(*Toronto*) – ISMP Canada supports the recommendations released today in the Long-Term Care Public Inquiry Report. The focus of the report is to ensure improvements to the care and safety of long-term care residents are made; a goal that is consistent with ISMP Canada’s commitment to advancing medication safety in all health care settings.

“Our thoughts today are with those affected by these circumstances and the tragic deaths that occurred.” said ISMP Canada CEO Carolyn Hoffman. “ISMP Canada was pleased to contribute expertise to the work of the Inquiry and we acknowledge Justice Gillese and her team for their in-depth review and strong recommendations for improvement.”

The Inquiry Report confirms the importance of timely medication incident reporting, analysis and learning processes in all Long-Term Care homes,” said Julie Greenall, Director of Projects and Education at ISMP Canada and an expert witness at the Inquiry. “Our approach to incident analysis at ISMP Canada is to seek to understand what happened and why it happened, then move to identify system changes that will prevent the needless harm and death of those receiving health care services.”

Several recommendations issued today are related to the tracking and reporting of the use of glucagon and other rescue agents. ISMP Canada supports these recommendations and commits to working with the Ministry of Health and Long-Term Care as well as long-term care homes to develop and implement a process for this purpose.

“This is a call to action for government, long-term care homes, regulators and other key stakeholders to develop and implement changes to improve medication safety,” said Ms. Hoffman. “ISMP Canada is looking forward to collaborating with those organizations identified in the Inquiry Report recommendations to prevent similar tragedies in the future.”



NEWS RELEASE

The **Institute for Safe Medication Practices Canada (ISMP Canada)** is an independent national not-for-profit agency committed to the advancement of medication safety in all health care settings. ISMP Canada works collaboratively with the health care community, regulatory agencies and policy makers, provincial, national, and international patient safety organizations, the pharmaceutical industry, and the public to promote safe medication practices. ISMP Canada's mandate includes receiving and analyzing medication incident and near-miss reports, identifying contributing factors and causes and making recommendations for the prevention of harmful medication incidents.

A Key Partner in the Canadian Medication Incident Reporting and Prevention System (CMIRPS)

www.ismp-canada.org | www.safemedicationuse.ca

MEDIA CONTACT:

Ellen Gardner
ISMP Canada Communications
416.893.2552 ellen.gardner@ismpcanada.ca